Articles from GE HealthCare Technologies Inc.

As part of a companywide commitment to advance innovation that improves the health of patients and the planet, GE HealthCare (Nasdaq: GEHC) is highlighting several solutions with increased focus on sustainability at the Radiological Society of North America (RSNA) 2024 Annual Meeting, which is held Dec. 1-4 in Chicago, IL.

Today GE HealthCare announced the new Pristina Via™* mammography system designed to enhance the screening experience for both technologists and patients. Debuting at the Radiological Society of North America’s 2024 Annual Meeting, this innovation provides mammography technologists with a suite of sophisticated tools that balance the demands of diagnostic accuracy and fast-paced workflows to facilitate more patient-centered breast care.

Today, GE HealthCare (Nasdaq: GEHC) and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced a strategic collaboration to further the innovation, commercialization, and adoption of AI in imaging. Together, the two companies aim to develop SmartTechnology™ solutions that harness the transformative power of AI to address key challenges across the imaging value chain, including helping increase the efficiency of imaging interpretation and reporting, enabling collaboration across care teams, improving the clinical interpretation of images, and enhancing operational efficiency and productivity. These new SmartTechnology solutions will seek to combine GE HealthCare’s imaging expertise and scale, RadNet’s deep experience in care delivery, and DeepHealth’s AI-powered health informatics portfolio to elevate patient care through improved end-to-end clinical and operational workflows.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare (Nasdaq: GEHC) today announced a new tile for its Command Center Software: Hospital Pulse. Hospital Pulse Tile pulls in real-time information from across departments to quickly surface the most vital information about a healthcare system’s operations in a customizable dashboard designed to give operation leaders the quick “pulse check” they need to make adjustments throughout the day. For example, the tile can be configured to show how the number of emergency department admissions today as compared to a six-month median or to show what the maximum post-anesthesia boarding time was in the last day. This new capability represents a key advancement in enhancing overall hospital efficiency, supporting both care teams and patients. Duke Health, a Command Center Software user since 2019, will be the first healthcare provider globally to implement Hospital Pulse Tile. Hospital Pulse Tile will be widely available to U.S. customers next year.

With the aim of increasing access to precision care, GE HealthCare is proud to collaborate with University Medicine Essen (UME) in the establishment of a new Theranostics Center of Excellence. The Center will be outfitted with the latest technologies and solutions to support the clinical practice and advanced research of more personalized approaches to cancer care in Germany and around the world.

GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Flyrcado™ (flurpiridaz F 18) injection, a first of its kind positron emission tomography myocardial perfusion imaging (PET MPI) agent, for the detection of coronary artery disease (CAD). Indicated for patients with known or suspected CAD, Flyrcado delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today. Flyrcado, which can be manufactured in an offsite pharmacy and delivered as a ready-to-use unit dose, has the potential to expand clinician and patient access to PET MPI, including improving diagnostic accuracy in difficult-to-image patients such as those with a high body mass index (BMI) and women1.

GE HealthCare (Nasdaq: GEHC) today announced the launch of enhanced Venue ultrasound systems and a new solution setting the pace of point-of-care ultrasound (POCUS): Venue Sprint. The Venue Sprint is a new ultrasound device designed for maximum portability that combines the powerful, familiar Venue software and AI-enabled tools, uncompromised image quality, and wireless probe capability with Vscan Air handheld ultrasound systems. Other Venue family ultrasound systems will also now offer wireless probe connectivity, supplementary advanced clinical tools and the latest ViewPoint™ 6 updates for increased efficiency and optimized workflow.

The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 15,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $86.00 per share. The Offering was upsized from the previously announced offering size of 10,000,000 GEHC Shares. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 10,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare (Nasdaq: GEHC) announced today that management will present at the following September investor conferences.

GE HealthCare (Nasdaq: GEHC) and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (Nasdaq: AMZN), today announced a strategic collaboration to develop purpose-built foundation models and generative artificial intelligence (AI) applications designed to help clinicians improve medical diagnostics and patient care. GE HealthCare has selected AWS as its strategic cloud provider and plans to use its healthcare and generative AI services to build and implement new, versatile foundation models to transform the future of healthcare. These new generative AI-powered workflows are intended to fast-track the delivery of innovations to streamline healthcare operations, increase diagnostic and screening accuracy, enhance outcomes, lower access hurdles, and promote equitable care, thereby easing provider workload and accelerating industry innovation.

GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent Ultrasound is a leader in integrated AI-driven image analysis tools designed to make ultrasound smarter and more efficient. GE HealthCare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease-of-use for the benefit of clinicians and patients.

GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the second quarter of 2024 payable on August 15, 2024 to all shareholders of record as of July 19, 2024.

GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website.

The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the first quarter of 2024 payable on May 15, 2024 to all shareholders of record as of April 19, 2024.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 14,000,000 shares of its common stock (the “GEHC Shares”). The Offering was upsized from the previously announced offering size of 13,000,000 GEHC Shares. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

Based on its long-term artificial intelligence (AI) partnership, GE HealthCare and Mass General Brigham plan to integrate medical imaging foundation models into their AI research work, with a strong focus on responsible AI practices. Both organizations have been working closely on AI solutions since announcing their 10-year commitment in 2017 to explore the use of AI across a broad range of diagnostic and treatment paradigms through sustainable AI development.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare (Nasdaq: GEHC) is announcing today that President and Chief Executive Officer, Peter Arduini, and Vice President and Chief Financial Officer, Jay Saccaro, will attend the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th in San Francisco. Both GE HealthCare executives will participate in a Q&A session following Arduini’s presentation at 2:15 pm ET/11:15 am PT.

The University of Wisconsin School of Medicine and Public Health at UW–Madison and GE HealthCare announced today a 10-year strategic collaboration that builds on an iconic relationship spanning more than 40 years. The new research collaboration expands the existing scope beyond medical imaging to new frontiers in digital technologies and disease-focused solutions.

GE HealthCare (Nasdaq: GEHC) today announced its Venue Family point-of-care ultrasound systems will now feature Caption Guidance, artificial intelligence (AI)-driven technology that provides real-time guidance to users for capturing diagnostic-quality cardiac images. The Venue Family is the first among GE HealthCare ultrasound products to incorporate this scan guidance technology following the company’s acquisition of Caption Health earlier this year. Caption Guidance is an optional add-on that offers new capabilities at the point of care, supporting clinicians in a wide range of clinical settings and practices such as emergency departments, critical care wards, and anesthesiology.

GE HealthCare (Nasdaq: GEHC) today released its inaugural Sustainability Report, which describes the steps the Company has taken to establish its stand-alone environmental, social, and governance (ESG) practice and infrastructure, as well as how it has bolstered the foundation put in place prior to its spin-off from GE. The report incorporates findings from GE HealthCare’s existing ESG materiality assessment, which informed the Company’s ESG strategy, and outlines the Company’s long-term ESG objectives and progress against previous goals.

Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.

GE HealthCare (Nasdaq: GEHC) has entered into a distribution agreement with DePuy Synthes*, the Orthopaedics Company of Johnson & Johnson, to bring GE HealthCare’s OEC 3D Imaging System, in conjunction with DePuy Synthes’ extensive product portfolio, to more surgeons and patients across the United States. This new collaboration demonstrates GE HealthCare’s ongoing commitment to bring exceptional imaging technologies to clinicians providing patient care through the practice of some of healthcare’s most complex spine procedures today.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $78.00 per share. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare (Nasdaq: GEHC) today announced the FDA clearance and launch of Sonic DL – a state-of-the-art deep learning-based technology designed to dramatically accelerate image acquisition in magnetic resonance imaging (MRI). Sonic DL enables new imaging paradigms, such as high-quality cardiac MRI in a single heartbeat. This breakthrough expands GE HealthCare’s industry-leading AI-enabled solutions portfolio.

GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, is announcing today that its President and CEO Peter Arduini will present at the Jefferies Healthcare Conference in New York City on June 7, 2023 from 10:30 am to 10:55 am ET.